Neumora Therapeutics, Inc. (NMRA) stock
NMRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.37−0.06 (-13.85%)
Close on Nov 16, 2026Market cap $69.43MP/E –Yield –
Neumora Therapeutics net income
Net income is the profit left for shareholders after every expense, interest and tax.
Neumora Therapeutics's net income for the twelve months ending Jun 30, 2026 was -$212.75M. For fiscal 2025 it was -$236.93M.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$236.93M | – |
| FY2024 | Dec 31, 2024 | -$243.79M | – |
| FY2023 | Dec 31, 2023 | -$235.93M | – |
| FY2022 | Dec 31, 2022 | -$130.90M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$43.08M | – |
| Q1 FY2026 | Mar 31, 2026 | -$53.46M | – |
| Q4 FY2025 | Dec 31, 2025 | -$59.45M | – |
| Q3 FY2025 | Sep 30, 2025 | -$56.76M | – |
| Q2 FY2025 | Jun 30, 2025 | -$52.73M | – |
| Q1 FY2025 | Mar 31, 2025 | -$67.99M | – |
| Q4 FY2024 | Dec 31, 2024 | -$58.82M | – |
| Q3 FY2024 | Sep 30, 2024 | -$72.55M | – |
| Q2 FY2024 | Jun 30, 2024 | -$58.70M | – |
| Q1 FY2024 | Mar 31, 2024 | -$53.72M | – |
| Q4 FY2023 | Dec 31, 2023 | -$108.73M | – |
| Q3 FY2023 | Sep 30, 2023 | -$53.03M | – |
| Q2 FY2023 | Jun 30, 2023 | -$38.54M | – |
| Q1 FY2023 | Mar 31, 2023 | -$35.63M | – |
| Q4 FY2022 | Dec 31, 2022 | -$28.15M | – |
| Q3 FY2022 | Sep 30, 2022 | -$29.34M | – |
| Q2 FY2022 | Jun 30, 2022 | -$30.37M | – |
| Q1 FY2022 | Mar 31, 2022 | -$43.04M | – |
See a number that looks wrong?